Literature DB >> 24841901

[Coexistent depressive and anxiety disorders in epilepsy and multiple sclerosis: a challenge to neuropsychiatric practice].

Hans-Peter Kapfhammer1.   

Abstract

The high rate of co-existent emotional disorders in major neurological disorders, such as epilepsy and multiple sclerosis is challenging. As a rule, this co-existence comprises a more dramatic subjective suffering, a reduced psychological coping, possible negative interferences with somatic treatments and rehabilitations, an impaired quality of life and higher grades of psychosocial disability. It may also lead to an overall increased risk of somatic morbidity and even mortality in the further course of illness. These complex interrelations may be favourably integrated within a biopsychosocial model. Psychological and psychosocial stressors can be appreciated on their own discrete levels, have to be reflected, however, in their neurobiological correlates. Both neurological and emotional disorders frequently share decisive pathogenetic mechanisms, i.e. the underlying process of neurological disease may contribute to major affective problems also in a somato-psychic direction. In addition, mutual interactions of both neurological and psychiatric treatments in their impact on the emotional and neurological risks have to be appreciated.

Entities:  

Mesh:

Year:  2014        PMID: 24841901     DOI: 10.1007/s40211-014-0105-y

Source DB:  PubMed          Journal:  Neuropsychiatr        ISSN: 0948-6259


  82 in total

1.  International consensus clinical practice statements for the treatment of neuropsychiatric conditions associated with epilepsy.

Authors:  Mike P Kerr; Seth Mensah; Frank Besag; Bertrand de Toffol; Alan Ettinger; Kousuke Kanemoto; Andres Kanner; Steven Kemp; Ennapadum Krishnamoorthy; W Curt LaFrance; Marco Mula; Bettina Schmitz; Ludgers Tebartz van Elst; Julian Trollor; Sarah J Wilson
Journal:  Epilepsia       Date:  2011-09-28       Impact factor: 5.864

2.  Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample.

Authors:  Lydia Chwastiak; Dawn M Ehde; Laura E Gibbons; Mark Sullivan; James D Bowen; George H Kraft
Journal:  Am J Psychiatry       Date:  2002-11       Impact factor: 18.112

Review 3.  Antidepressant therapy in epilepsy: can treating the comorbidities affect the underlying disorder?

Authors:  L Cardamone; M R Salzberg; T J O'Brien; N C Jones
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

4.  Symptom overlap in anxiety and multiple sclerosis.

Authors:  Seán Ó Donnchadha; Teresa Burke; Jessica Bramham; Marie Claire O'Brien; Robert Whelan; Richard Reilly; Hanni Kiiski; Róisín Lonergan; Katie Kinsella; Siobhán Kelly; Christopher McGuigan; Michael Hutchinson; Niall Tubridy
Journal:  Mult Scler       Date:  2013-02-14       Impact factor: 6.312

5.  Lesions in the left arcuate fasciculus region and depressive symptoms in multiple sclerosis.

Authors:  J Pujol; J Bello; J Deus; J L Martí-Vilalta; A Capdevila
Journal:  Neurology       Date:  1997-10       Impact factor: 9.910

Review 6.  The treatment of depressive disorders in epilepsy: what all neurologists should know.

Authors:  Andres M Kanner
Journal:  Epilepsia       Date:  2013-03       Impact factor: 5.864

7.  Predictors of psychiatric and seizure outcome following temporal lobe epilepsy surgery.

Authors:  Rebecca A Cleary; Pamela J Thompson; Zoe Fox; Jacqueline Foong
Journal:  Epilepsia       Date:  2012-08-06       Impact factor: 5.864

8.  Alcohol and drug abuse among persons with multiple sclerosis.

Authors:  C H Bombardier; K D Blake; D M Ehde; L E Gibbons; D Moore; G H Kraft
Journal:  Mult Scler       Date:  2004-02       Impact factor: 6.312

9.  Psychiatric comorbidity in epilepsy: a population-based analysis.

Authors:  Jose F Tellez-Zenteno; Scott B Patten; Nathalie Jetté; Jeanne Williams; Samuel Wiebe
Journal:  Epilepsia       Date:  2007-07-28       Impact factor: 5.864

10.  Prospective examination of anxiety and depression before and during confirmed and pseudoexacerbations in patients with multiple sclerosis.

Authors:  Michelle Nicole Burns; Ewa Nawacki; Juned Siddique; Daniel Pelletier; David C Mohr
Journal:  Psychosom Med       Date:  2012-11-28       Impact factor: 4.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.